SCHEMBL21247218

SCHEMBL21247218

COC(=O)c1c(NC(=O)c2ccc(Br)cc2)sc2c1CC(C)(C)CC2

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.60
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ TNF P01375 2/20 0.54
▸ NOD1 Q9Y239 2/20 0.54
▸ RAB7A P51149 1/20 0.53
▸ FLT3 P36888 1/20 0.53
▸ MAPK1 P28482 2/20 0.50
▸ USP2 O75604 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ ALDH1A1 P00352 3/20 0.49
▸ TDP1 Q9NUW8 2/20 0.49
▸ THRB P10828 2/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ NPSR1 Q6W5P4 2/20 0.49
▸ LMNA P02545 2/20 0.49
▸ HPGD P15428 2/20 0.49
▸ TP53 P04637 1/20 0.48
▸ KIF11 P52732 1/20 0.48
▸ GLA P06280 1/20 0.46
▸ GLO1 Q04760 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21247181 0.93 MAPT (0.59) MAPTSMN1; SMN2TNFNOD1FLT3
SCHEMBL21247202 0.89 TNF (0.68) MAPTSMN1; SMN2TNFNOD1RAB7A
SCHEMBL21259035 0.79 MAPT (0.49) MAPTSMN1; SMN2RAB7AMAPK1USP2
SCHEMBL21247382 0.79 RAB7A (0.80) MAPTSMN1; SMN2TNFNOD1RAB7A
SCHEMBL21247301 0.78 MAPT (0.53) MAPTSMN1; SMN2MAPK1USP2HSD17B10
SCHEMBL21247188 0.76 NOD1 (0.71) MAPTSMN1; SMN2TNFNOD1RAB7A
SCHEMBL21247255 0.76 USP2 (0.54) MAPTSMN1; SMN2MAPK1USP2HSD17B10
SCHEMBL21247199 0.75 MAPT (1.00) MAPTTNFNOD1FLT3MAPK1
SCHEMBL21247263 0.75 MAPT (0.96) MAPTSMN1; SMN2TNFNOD1FLT3
SCHEMBL19321160 0.75 RAB7A (0.62) MAPTSMN1; SMN2TNFNOD1RAB7A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11492347-B2 Fused thiophene derivatives and their uses ENYO PHARMA (FR) 2022-11-08 — — US disclosed
EP-3749659-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO Pharma (FR) 2020-12-16 — — EP disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH MAPT 2107/4885SMN1; SMN2 4008/4885TNF 1354/4885
US-11492347-B2 Fused thiophene derivatives and their uses FTH1, SLC40A1, FECH MAPT 2107/4885SMN1; SMN2 4008/4885TNF 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback